Showing 1491-1500 of 19292 results for "".
Hepatocellular Carcinoma: Examining Its Prevalence and Prognostic Biomarkers
https://reachmd.com/programs/project-oncology/hepatocellular-carcinoma-examining-its-prevalence-and-prognostic-biomarkers/24479/Join us as we explore the prevalence of hepatocellular carcinoma along with potential prognostic biomarkers that are currently being investigated.The Future of ITP Care: Exploring New Treatments
https://reachmd.com/programs/project-oncology/the-future-of-itp-care-exploring-new-treatments/26404/Learn about how new immune thrombocytopenia treatment options, including BTK inhibitors and immune therapies.Interdisciplinary Management of Gynecologic Cancers
https://reachmd.com/programs/cme/Interdisciplinary-Management-of-Gynecologic-Cancers/39286/Multidisciplinary experts explore biomarker-driven strategies, immunotherapy, and personalized care in cervical and endometrial cancer management.Supplements and Cannabis in Breast Cancer Care: An Integrative Medicine Approach
https://reachmd.com/programs/project-oncology/supplements-and-cannabis-in-breast-cancer-care-an-integrative-medicine-approach/26409/Here’s how we can use an integrative medicine approach to balance evidence-based guidance on supplements and cannabis with patients’ goals.Diagnosing IgA Nephropathy: The Role of Immunofluorescence and Immunohistochemistry
https://reachmd.com/programs/frontlines-iga-nephropathy/diagnosing-iga-nephropathy-the-role-of-immunofluorescence-and-immunohistochemistry/26943/How is IgA nephropathy diagnosed and differentiated from similar diseases? Tune in to find out.The Future of IgA Nephropathy: Why Biomarkers Matter
https://reachmd.com/programs/frontlines-iga-nephropathy/the-future-of-iga-nephropathy-why-biomarkers-matter/26942/Dive into the importance of biomarkers in the intensifying pursuit of newer, more effective treatments for IgA nephropathy.Anti-Amyloid Therapy in Early Alzheimer’s Disease: Real-World Experience and Innovation
https://reachmd.com/programs/medical-industry-feature/anti-amyloid-therapy-early-alzheimers-real-world/48941/Explore the clinical use of the anti-amyloid therapy LEQEMBI® (lecanemab-irmb) for early Alzheimer’s disease in this four-part, on-demand video series. The program offers expert-led guidance on patient selection and monitoring, 4-year efficacy and safety data, and emerging real-world evidence. FeatuDato-DXd in Non-Small Cell Lung Cancer: Implications of TROPION-Lung01 Data
https://reachmd.com/programs/project-oncology/dato-dxd-nsclc-tropion-lung01-data/36610/As brain metastases continue to complicate treatment decisions in advanced non-small cell lung cancer (NSCLC), recent evidence is shifting the therapeutic landscape. Data from a post-hoc analysis of TROPION-Lung01—presented at the 2025 World Conference on Lung Cancer—demonstrate meaningful intracraISDPA: Dr. Bhatia on JAK Inhibitors
https://practicaldermatology.com/conferences/isdpa-midwest-derm-2024/isdpa-dr-bhatia-jak-inhibitors/27064/Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, talks about his presentation on JAK inhibitors at the Illinois Society of Dermatology Physician Assistants (ISDPA) Midwest Dermatology Conference 2024."A big revolution is coming in ultrasound," says Dr. Clément Papadacci from Inserm
https://reachmd.com/programs/the-convergence/ultrasound-clement-papadacci-inserm/39926/4D ultrasound and ultrasound localization microscopy (ULM) are reshaping non-invasive imaging, allowing clinicians to visualize entire organs—down to vessels smaller than a human hair—in dynamic, real-time detail. Dr. Clément Papadacci joins Dr. Brian McDonough to share how his groundbreaking probe